DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Eris Lifesciences Limited — Investor Presentation

NSE 1 hr ago·26 Oct 2026, 8:25 am

Eris Lifesciences

Eris Lifesciences Limited has informed stock exchanges that it will present its investor presentation. This document typically outlines the company's financial performance, strategic plans, and future outlook for the upcoming period. Such updates are a routine part of corporate governance, allowing the management to communicate directly with shareholders and the market.

For investors, this update provides a crucial opportunity to gauge the company's direction. It offers insights into how Eris plans to navigate the competitive pharmaceutical landscape and achieve its growth targets. Monitoring the key takeaways from this presentation can help retail investors assess the company's operational health and long-term prospects.

Investors should watch for management commentary on revenue growth, margin expansion, and new product launches. Any guidance provided regarding future earnings or market share will be significant. Keeping an eye on these details will help you better understand the company's trajectory and make informed decisions.